Guna-IL-11

Guna-IL-11 is a low-dose cytokine medicinal product developed by Guna S.p.a. as part of its Low Dose Medicine (LDM) therapeutic platform. LDM utilizes biological signaling molecules, such as cytokines, at physiological concentrations (typically in the picogram to nanogram range) to modulate the immune system and restore homeostatic balance. Guna-IL-11 acts as an agonist of the interleukin-11 receptor, leveraging the cytokine's natural anti-inflammatory and immunomodulatory properties. It is primarily being developed for the treatment of psoriasis, where it is often investigated as part of a multicomponent therapeutic regimen involving other low-dose cytokines like IL-4 and IL-10. The formulation is typically administered as an oral solution for sublingual absorption.

Brand names

Guna-IL-11Guna-IL11Guna-IL 11

Other names

low-dose interleukin-11Guna-Interleukin 11Guna-Interleukin11Guna-Interleukin-11